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n the late 1970s, catheter-based therapy for the percutaneous management of pa-
tients with coronary artery disease (CAD) was introduced. At that time, coronary
artery bypass surgery (CABG) was the sole interventional treatment available for
patients with CAD and offered superior outcomes to medical therapy in many
patients.1 This new interventional but less invasive treatment, percutaneous coronary
intervention (PCI), was met with skepticism, disdain, and dismissive arrogance from
within the surgical community. Attitudes manifested by statements such as ‘‘we have
a superior procedure,’’ ‘‘angioplasty will never work,’’ or ‘‘outcomes are being com-
promised’’ only served to foster complacency and stifle surgical innovation. This
comfort in complacency within the surgical community was further reinforced by
the annual increase in CABG procedural volume that continued for 20 years after
the introduction of catheter-based therapy2 (Figure 1). However, the field of PCI pro-
gressed rapidly, catalyzed by incremental improvements in technique and technology
including steerable catheters, stents, drug-eluting stents, and adjuvant pharmacology.
These advancements both decreased procedural morbidity and improved outcomes so
that within 10 years after the first interventional coronary procedure was reported, pro-
cedural volume of PCI eclipsed that of CABG. So much has the treatment paradigm
continued to shift that currently in clinical practice, both interventionalists and their
patients often view CABG as the procedure of last resort; the default treatment deci-
sion is frequently ‘‘if it can’t technically be stented, then we’ll have to do surgery.’’
We are now just over 5 years into the brave new world of transcatheter therapy of
valvular heart disease, and there are certain similarities to the changing practice par-
adigm that we witnessed in the early years of PCI in the management of patients with
CAD. Since the first report of successful percutaneous aortic valve implantation, all
four cardiac valves have now been successfully treated by catheter techniques.3 There
is now regulatory approval for the commercial sale of two devices for the treatment of
aortic stenosis, and one device for the management of mitral insufficiency is in a US
pivotal trial.4,5 Is this the history of coronary intervention being repeated, that is, de´ja`
vu all over again? There is enough evidence already that this is indeed the case and
that, as surgeons, we should learn the lessons of the past.
It is instructive to first view a snapshot of the first 5 years of this new therapy,
examine the accomplishments, assess the current barriers, and then suggest how to
better create and participate in the future. The pioneering work of Lurz, Bonhoeffer
and associates6 has resulted in excellent results in the transcatheter management of
children and young adults with degenerated right ventricular outflow tract conduits.
A total of 417 implants have now been performed with a bovine jugular valve sutured
in a nitinol self-expanding stent, the Melody Transcatheter Valve (Medtronic, Inc,
Minneapolis, Minn. Results are available on the first 301 patients with 294 (97.7%)
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Mack Expert CommentaryFigure 1. Procedural volumes of coro-
nary revascularization. PCI, Percutane-
ous coronary intervention; CABG,
coronary artery bypass grafting. (Repro-
duced with permission from The Advi-
sory Board Company, Future of Cardiac
Surgery—2004,  The Advisory Board
Company, 2004.)successful implantations, 284 (94.4%) treated patients alive,
and only 16 (5%) implanted valves explanted. This valve has
received CE Mark approval for commercial sale in Europe
and is currently in an expanded US feasibility trial. Most pro-
cedures have been performed by an antegrade transfemoral
venous approach, although a few procedures have been per-
formed through a right ventricular transapical access. Chal-
lenges include treatment of patients in need of larger size
valves and those with native pulmonary valve disease and
transannular patches.
The first report of a transcatheter aortic valve implantation
was by Cribier and colleagues3 in 2002. The initial proce-
dures were performed by an antegrade, femoral, transseptal
venous approach; however, the ability to reproduce similar
results in other centers was an issue. Two other approaches
were developed to address this—a retrograde transfemoral,
arterial approach and an antegrade transapical approach.
The transfemoral approach was facilitated by the develop-
ment of a flexible delivery catheter capable of negotiating
the aortic arch and traversing the stenotic valve in a retrograde
fashion. The early developmental work of this approach was
by Webb and coworkers4 from Vancouver, who now have
the largest experience. The transapical procedure was largely
developed by Walther and colleagues7 in Leipzig, who now
have the largest experience with this approach. This device,
the Sapien THV (Edwards Lifesciences, Irvine, Calif), is
a balloon-deployed tissue valve mounted in a stainless steel
stent. This valve has recently been approved for commercial
sale in Europe with now more than 1000 valves implanted,
currently at a rate of more than 20 per week. Candidates
for implantation include inoperable or high-risk operable pa-
tients with procedure mortality ranging between 5% and 10%
in most centers and 1-year survival between 70% and 75%.8
The US pivotal randomized trial of this valve is underway
with enrollment in the 1000-patient trial over 25% completed
and commercial approval expected possibly in 2011.The Journal of ThoA second transcatheter aortic valve, the CoreValve Re-
valving System (CoreValve, Inc, Irvine, Calif) is a nitinol,
self-expanding bovine tissue valve delivered percutaneously
with an 18F system by transfemoral approach without gen-
eral anesthesia.5 This device has also received regulatory ap-
proval for commercial sale in Europe with a like number of
implants performed with results generally equivalent to those
of the Sapien valve. There is early clinical feasibility demon-
strated with at least three other catheter-delivered aortic
valves. The Direct Flow Medical Valve (Direct Flow Medi-
cal, Santa Rosa, Calif) has been successfully implanted in
11 patients in Germany, the Sadra Lotus Valve (Sadra Med-
ical, Campbell, Calif) in 3 patients, and the AorTx (Hansen
Medical, Mountain View, Calif) in 3 patients. There is also
a pipeline full of innovative valve designs that promise to
overcome some of the limitations of the early-generation de-
vices, including enhanced deliverability, retrievability, and
the ability to be repositioned. As enhanced delivery, safety,
and valve durability are demonstrated, indication for implan-
tation into lower-risk patients is inevitable.
Although promising in the early stages of clinical applica-
tion, the path to the demonstration of clinical efficacy has
been a more arduous one for the percutaneous treatment of
mitral valve disease. Demonstration of proof of principle
for the treatment of mitral regurgitation (MR) from both in-
trinsic and functional etiologies has occurred. Devices that
replicate the Alfieri ‘‘edge-to-edge’’ approach have been
used primarily for degenerative disease, although there is
some early evidence that functional MR could also possibly
be treated by this technique.9 One device, the Evalve Mitra-
Clip (Evalve, Inc, Menlo Park, Calif), has completed a feasi-
bility trial, a high-risk registry, and is nearing completion of
enrollment in a pivotal randomized trial comparing the percu-
taneous clip to conventional mitral valve repair. A second de-
vice, the Edwards Mobius, which performed an edge-to-edge
approximation using a suture-based system rather than a clip,racic and Cardiovascular Surgery c Volume 136, Number 4 817
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bility trial.
A host of devices to remodel the mitral annulus either via
the coronary sinus or directly in patients with functional MR
are in clinical investigation. Although isolated proof of con-
cept, safety, and some early clinical efficacy has been demon-
strated with a number of catheter-delivered devices, progress
has been slower than anticipated. One issue is lack of
certainty regarding the role for correction of MR in heart fail-
ure even under optimal open surgical conditions. This uncer-
tainty stems from the fact that MR in heart failure is due to
failure of leaflet coaptation from ventricular dilation and api-
cal lateral distraction of the papillary muscles tethering the
mitral leaflets and only secondarily to annular dilation. Fur-
ther complicating factors include the variability in the rela-
tionship between the coronary sinus and the posterior
mitral annulus and the intervening coronary artery that fre-
quently occurs between the coronary sinus and the mitral
annulus. Other devices that have preclinical proof of princi-
ple and/or early clinical experience include those that do
not use the coronary sinus but remodel the annulus directly
either by suture, device, or by radiofrequency shrinkage. Still
other devices are designed to remodel the annulus secondar-
ily by first reconfiguring the shape of the left ventricle
(iCoapsys; Myocor, Maple Grove, Minn) or left atrium
(PS3; Ample Medical, Foster City, Calif). Other devices
are focused on correcting MR by placement of artificial cords
to the mitral leaflets by a minimally invasive approach (Neo-
chord Inc, Wayzata, Minn; Transcardiac Therapeutics,
Atlanta, Ga). An even more intriguing concept includes
that of percutaneous mitral valve replacement (EndoValve
Inc, Princeton, NJ).
The progress in the introduction of catheter-based therapy
has been more rapid than expected for aortic stenosis, slower
than anticipated for MR, and has achieved excellent early
results in right ventricular conduits. It must be remembered
that these results have been achieved with early-stage devices
and delivery systems in clinical situations in which both ap-
propriate patient selection and procedural techniques are
evolving. There is a pipeline full of the next generation of de-
vices backed by strong financial investment and creative
engineering minds that will likely solve the challenges en-
countered by these first-generation devices.
How do we as a surgical community react and adapt to this
potential change in the management of valvular heart disease
that is bound to affect our current practice? First, we should
not become complacent by the fact that currently the number
of valve operations is increasing. Just as in the world of cor-
onary revascularization, in which the first two decades wit-
nessed a continuous increase in the annual volume of
CABG procedures, we are likely to see the same increase
in surgical valve procedures for the foreseeable future. There
are many reasons for this, including the wider availability of
diagnostic imaging, greater recognition that valvular heart818 The Journal of Thoracic and Cardiovascular Surgery c Octdisease is underdiagnosed and undertreated, and new studies
supporting treatment of asymptomatic patients. The potential
of percutaneous therapy has also brought added focus to this
field. However, just as the annual number of coronary proce-
dures performed by a percutaneous approach exceeded those
done by a surgical one for a decade after introduction, the
same relative growth rates are likely to be seen in the treat-
ment of valve disease as it is affected by the emerging field
of transcatheter valve therapy. Whether this shift will occur
within a decade or longer is impossible to predict owing to
the unpredictability of many variables including device iter-
ation, clinical trial results, and regulatory and reimbursement
issues; however. this shift will indeed happen!
We as a cardiac surgical community have a choice; we can
stand by on the sidelines and witness this shift with skepti-
cism and disparagement as we did PCI, or we can choose
to participate. The role that surgeons and the surgical commu-
nity are going to play is to a large degree up to us. If we want
to act like a ‘‘guild’’ with a protectionist attitude toward our
members, then we are likely to see the size of our specialty
decrease and our role in the management of valvular heart
disease diminish. However, if we wish to maintain a promi-
nent role in the management of valvular heart disease, then
we need only look as far as our sister specialty of vascular
surgery to learn how to adapt. Vascular surgeons evaluated
the changing treatment paradigms of vascular disease man-
agement as catheter therapy became more versatile and ad-
vanced. They elected to learn the skill sets necessary to
participate in catheter-based therapy. Whereas 10 years ago
vascular surgery was a specialty performing predominantly
open vascular operations, most successful vascular surgery
practices are now largely endovascular ones. The specialty
as a whole and surgeons as individuals took it upon them-
selves to assess the treatment landscape, learn new skill
sets heretofore lacking, embrace change, and critically ana-
lyze results. As a result, vascular surgeons now possess the
ability to choose an open or endovascular procedure or a hy-
brid of both depending on specific patient needs. I suggest
that it would be prudent for us as cardiac surgeons to take
this approach, work collaboratively with our interventional
colleagues who have skill sets and perspectives different
from ours, and participate in a constructive manner of devel-
oping and implementing new and appropriate treatment par-
adigms for patients with valvular heart disease.
We have a proud heritage in cardiac surgery that has seen
miraculous therapies introduced that have benefited our pa-
tients over the past half century. However, the specialty of car-
diac surgery is currently in a crisis mode; training positions are
going unfilled, the workforce is disheartened, and the best and
the brightest are no longer attracted to our field. It is time to
reinvent our specialty and ourselves. The leadership of four
major organizations in cardiothoracic surgery, The American
Association for Thoracic Surgery (AATS), the American
Board of Thoracic Surgery (ABTS), The Society of Thoracicober 2008
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search and Education (TSFRE) have recently set forth a man-
date for change in which graduate and postgraduate education
will be totally revamped to address the current situation. As
critical as the opportunities that this initiative will create, we
as individuals cannot wait for this to be fixed for us. Change
must come from within. We must critically analyze our own
situations, keep what is good, discard that which is arcane
and outmoded, have the wisdom to know the difference,
and embrace the opportunities presented.
Nowhere else will that mandate for change and the adop-
tion of new treatment paradigms and skill sets be more evi-
dent that in the field of valvular heart disease. We have
already seen this shift, not only in the interventional manage-
ment of coronary artery disease but also in vascular disease,
general surgery, and orthopedic surgery. Patients will choose
the less invasive approach over a more invasive one even
when they understand that the efficacy and duration of the
treatment benefit may not initially be as great with the less in-
vasive approach. However, progress is inexorable and even-
tually the benefits of new, less invasive procedures equal or
surpass those of their open predecessors, for example, laparo-
scopic cholecystectomy and arthroscopy.
We must not be complacent regarding our role as surgeons
in valvular heart disease. We have superlative outcomes man-
ifest by decreasing mortality in the face of an aging popula-
tion with increasingly complex disease, increasing valve
repair rates, and higher referral rates, especially for the man-
agement of asymptomatic disease. However, just as in the
dawn of the age of PCI, we have the choice; we can rest onThe Journal of Thoour laurels, stand by our outcomes, and disparage the new
treatments being invented. Alternatively, we can learn from
the past, embrace change, gain the skill sets needed to partic-
ipate and thrive, and be part of the process rather than be un-
engaged bystanders.
Fool me once, shame on you; fool me twice, shame on me!
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